Heart failure & cardiomyopathiesDiagnostic or prognostic study
Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size
- Prognostic cohort study
Authors' conclusion
CH predicts cardiac death and all-cause mortality in DCM patients with optimal thresholds for clone size of 0.36% and 0.06%, respectively. Therefore, CH is prognostically relevant, independent of clone size in patients with DCM.
Study context
- Population
- Patients with nonischemic dilated cardiomyopathy (DCM)
- Participants
- 520 patients
- Comparison
- Clonal hematopoiesis (CH) vs no CH
- CHn = 109
- Outcome
- Cardiac death and all-cause mortality
- Follow-up
- Median 6.5 years (IQR: 4.7-9.7 years)
Performance
As reported in the abstract
CH vs No CHHazard ratio (95% CI)
cardiac death; VAF cutoff 0.36%
2.33(1.24–4.40)
all-cause mortality; VAF cutoff 0.06%
1.72(1.10–2.69)
Further findings
- Prevalence of CH driver mutations
- 21% · 109 of 109
Original publication
Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size. JACC Heart Fail. Published 25 August 2023. doi:10.1016/j.jchf.2023.06.037
Summarised from the published abstract; every number is checked against it